Haleon plc (HLN) Stock Score, Valuation & Financial Research
Haleon plc is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 42/100.
Quick answer for HLN
Haleon plc currently has a Wall Street Score of 42/100. The stored market price is $9.21. Its financial score is 22/100. Its valuation score is 22/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Haleon plc does
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdo
HLN financial snapshot
- Wall Street Score:
- 42/100
- Current price:
- $9.21
- Market capitalization:
- $40.56B
- Revenue:
- $26.14B
- Net income:
- $3.82B
- Free cash flow:
- $2.66B
- Cash:
- $1.11B
- Total debt:
- $11.07B
- EPS:
- 0.49
- P/E ratio:
- 19.0x
- Financial score:
- 22/100
- Valuation score:
- 22/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.8%.
- Free cash flow is $2.66B, showing positive cash generation.
- The balance sheet shows $1.11B of cash versus $11.07B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: HLN increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 22/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 22/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HLN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.